Drawing for MPD

USPTO serial 75843597

MPD

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
JOHNSON, AISHA CLARKE
Law office
TMEG LAW OFFICE 105 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with MPD?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

MARK I PEROFF

MARK I PEROFF KIRKPATRICK & LOCKHART LLP599 LEXINGTON AVENEW YORK, NY 10022-6030UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005PHARMACEUTICAL PREPARATIONS FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Feb 22, 2005MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Feb 22, 2005ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jul 27, 2004CNSIINQUIRY AS TO SUSPENSION MAILED—
Mar 27, 2004TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 9, 2004CNSLLETTER OF SUSPENSION MAILED—
Dec 9, 2003CFITCASE FILE IN TICRS—
Nov 14, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 14, 2003TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 16, 2003CNSIINQUIRY AS TO SUSPENSION MAILED—
Oct 22, 2002CNSLLETTER OF SUSPENSION MAILED—
Sep 26, 2002CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 3, 2002CNSIINQUIRY AS TO SUSPENSION MAILED—
Mar 14, 2002DOCKASSIGNED TO EXAMINER—
Feb 7, 2001CNSLLETTER OF SUSPENSION MAILED—
Sep 8, 2000CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 16, 2000CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 8, 2000DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance